Literature DB >> 7046847

Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion.

H G Braine, L L Sensenbrenner, S K Wright, P J Tutschka, R Saral, G W Santos.   

Abstract

Twenty-five patients with major ABO blood group incompatibility between donor and recipient underwent allogeneic bone marrow transplantation using erythrocyte depletion of the bone marrow infusate prior to administration. Over 95% of the original erythrocyte content of the marrows was removed, while retaining 75% of the mononuclear cell content and 57% of the granulocyte-monocyte colony-forming units. Recipients, well hydrated and premedicated with corticosteroids, diphenhydramine, and mannitol, tolerated infusions well. The frequency of engraftment, rate of recovery of peripheral blood leukocytes, granulocytes, and platelets, and the incidence of graft-versus-host disease was similar to that observed following ABO blood group compatible bone marrow transplantation. Erythroid development following ABO blood group incompatible transplantation was significantly impaired until hemagglutinins fell to 1:4 or lower, at which time recovery of erythrocytes was detected in the peripheral blood. The erythrocyte hypoplasia associated with incompatible hemagglutinins was temporary. Erythrocyte purging is a safe and effective technique to perform bone marrow transplantation across major ABO blood group incompatibilities.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046847

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  The processing of stem cell concentrates from the bone marrow in ABO-incompatible transplants: how and when.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Cecilia Rossi; Alessandro Lanti; Gaspare Adorno; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2013-11-21       Impact factor: 3.443

Review 2.  Anaesthetic implications for bone marrow transplant recipients.

Authors:  R A Stein; M J Messino; E A Hessel
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

Review 3.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

4.  Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.

Authors:  Gordana Tomac; Ines Bojanić; Sanja Mazić; Ivana Vidović; Mirela Raos; Branka Golubić Ćepulić; Ranka Serventi Seiwerth; Jadranka Kelečić; Boris Labar
Journal:  Blood Transfus       Date:  2017-04-19       Impact factor: 3.443

5.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

6.  Acquired immune haemolysis by anti A 1 antibody following bone marrow transplantation.

Authors:  R J Haas; P Rieber; M Helmig; E Strobel; B H Belohradsky; M U Heim
Journal:  Blut       Date:  1986-11

7.  Immunoadsorption for removal of anti-A and anti-B blood group antibodies in ABO-incompatible bone marrow transplantation.

Authors:  B Osterwalder; A Gratwohl; C Nissen; B Speck
Journal:  Blut       Date:  1986-11

Review 8.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

Review 9.  Bone marrow transplantation.

Authors:  T S Vats
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

10.  The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann syndrome.

Authors:  Yasuhiro Ebihara; Atsushi Manabe; Toshihisa Tsuruta; Kumiko Ishikawa; Daisuke Hasegawa; Yoshitoshi Ohtsuka; Hirohide Kawasaki; Kazuo Ogami; Yuka Wada; Tadayasu Kanda; Kohichiro Tsuji
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.